文章摘要

文章信息/Info

Title:: Preparation and performance verification of nano-photosensitizer UBI/PCN-224 targeting Staphylococcus aureus

作者:: 闫睿1; 李梦乔2; 柴韶斌2; 汪茜2△; （1.中国人民解放军总医院第三医学中心胸外科，北京 100039；2.中国人民解放军总医院第三医学中心急诊科，北京 100039）

Author(s):: YAN Rui1; LI Mengqiao2; CHAI Shaobin2; WANG Qian2; (1. Thoracic Surgery Department of the Third Medical Center of Chinese PLA General Hospital, Beijing 100039，China; 2. Emergency Department of the Third Medical Center of Chinese PLA General Hospital, Beijing 100039)

Keywords:: Porphyrin; Nano-photosensitive materials; Antimicrobial photodynamic therapy; Staphylococcus aureus; Antibacterial peptide

摘要:: 为抑制金黄色葡萄球菌，减少皮肤和软组织等发生感染，本研究基于抗菌肽和卟啉光敏剂，使用溶剂热法合成构建了可靶向金黄色葡萄球菌的纳米光敏剂UBI/PCN-224。使用透射电镜、激光粒度仪、光谱仪检测其形态表征和明暗环境下单线态氧产生的效果。然后将纳米光敏剂与金黄色葡萄球菌混合培养，使用扫描电镜观测靶向结合与杀菌能力。结果表明，本研究成功制备出的粒径大小为80 nm的靶向纳米光敏剂UBI/PCN-224，可结合金黄色葡萄球菌形成直径超过100 μm的聚合物。在光照2 min后，即可产生具有杀菌作用的活性氧成分。本研究制备的纳米光敏剂UBI/PCN-224可作为新型靶向抗菌剂应用于耐药细菌感染治疗中。

Abstract:: In order to control Staphylococcus aureus and reduce skin and soft tissue infections.Based on antimicrobial peptides UBI and porphyrin photosensitivities, we synthesized nano-photosensitizer UBI/PCN-224 that could target Staphylococcus aureus by solvothermal synthesis. The transmission electron microscopy, laser particle size analyzer, spectrometer were used to detect its morphological characterization and the effect of singlet oxygen production in light and dark environments.Then the nano-photosensitizer was mixed with Staphylococcus aureus for culture, and the targeted binding and bactericidal ability was observed by scanning electron microscopy.The results showed that the targeted nano-photosensitizer UBI/PCN-224 with a particle size of 80 nm was successfully prepared, which could combine with Staphylococcus aureus to form polymers with a diameter of more than 100 μm, and reactive oxygen components with bactericidal effect could be produced after 2 min under light. The nano-photosensitizer UBI/PCN-224 can be used as a novel targeted antibacterial agent in the treatment of drug-resistant bacterial infections.